TNFRSF10B and breast cancer: An ex vivo and in vivo potent DR5 agonist that induces regression of in situ tumors and inhibits the growth of metastatic TNBCs, showing therapeutic potential in patients with BC, especially those with basal B TNBC (Greer et al., 2019)